TDOC Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of -7.56% compared to Teladoc Health's net margin of -1.05%. Teladoc Health's return on equity of -54.92% beat Astrana Health's return on equity of 9.13%.

Teladoc Health has a consensus price target of $10.64, signalling upside risk potential of 31.51%. On the other hand Astrana Health has an analysts' consensus of $51.9000 which suggests that it could grow by 67.26%. Given that Astrana Health has higher upside potential than Teladoc Health, analysts believe Astrana Health is more attractive than Teladoc Health.

Teladoc Health has a beta of 1.267, which suggesting that the stock is 26.711% more volatile than S&P 500. In comparison Astrana Health has a beta of 1.044, suggesting its more volatile than the S&P 500 by 4.384%.

Teladoc Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teladoc Health pays -- of its earnings as a dividend. Astrana Health pays out 9.35% of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teladoc Health quarterly revenues are $640.5M, which are smaller than Astrana Health quarterly revenues of $665.2M. Teladoc Health's net income of -$48.4M is lower than Astrana Health's net income of -$7M. Notably, Teladoc Health's price-to-earnings ratio is -- while Astrana Health's PE ratio is 34.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teladoc Health is 0.54x versus 0.73x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Biote has a net margin of -7.56% compared to Teladoc Health's net margin of 7.43%. Teladoc Health's return on equity of -54.92% beat Biote's return on equity of --.

Teladoc Health has a consensus price target of $10.64, signalling upside risk potential of 31.51%. On the other hand Biote has an analysts' consensus of $7.47 which suggests that it could grow by 124.22%. Given that Biote has higher upside potential than Teladoc Health, analysts believe Biote is more attractive than Teladoc Health.

Teladoc Health has a beta of 1.267, which suggesting that the stock is 26.711% more volatile than S&P 500. In comparison Biote has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Teladoc Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biote offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teladoc Health pays -- of its earnings as a dividend. Biote pays out 150.27% of its earnings as a dividend.

Teladoc Health quarterly revenues are $640.5M, which are larger than Biote quarterly revenues of $49.8M. Teladoc Health's net income of -$48.4M is lower than Biote's net income of $3.7M. Notably, Teladoc Health's price-to-earnings ratio is -- while Biote's PE ratio is 18.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teladoc Health is 0.54x versus 0.58x for Biote. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of -7.56% compared to Teladoc Health's net margin of 13.04%. Teladoc Health's return on equity of -54.92% beat Cryo-Cell International's return on equity of --.

Teladoc Health has a consensus price target of $10.64, signalling upside risk potential of 31.51%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 33.44%. Given that Cryo-Cell International has higher upside potential than Teladoc Health, analysts believe Cryo-Cell International is more attractive than Teladoc Health.

Teladoc Health has a beta of 1.267, which suggesting that the stock is 26.711% more volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.607, suggesting its less volatile than the S&P 500 by 39.282%.

Teladoc Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 7.85% to investors and pays a quarterly dividend of $0.25 per share. Teladoc Health pays -- of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend.

Teladoc Health quarterly revenues are $640.5M, which are larger than Cryo-Cell International quarterly revenues of $8.1M. Teladoc Health's net income of -$48.4M is lower than Cryo-Cell International's net income of $1.1M. Notably, Teladoc Health's price-to-earnings ratio is -- while Cryo-Cell International's PE ratio is 134.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teladoc Health is 0.54x versus 1.63x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners has a net margin of -7.56% compared to Teladoc Health's net margin of -12.84%. Teladoc Health's return on equity of -54.92% beat P3 Health Partners's return on equity of -26.35%.

Teladoc Health has a consensus price target of $10.64, signalling upside risk potential of 31.51%. On the other hand P3 Health Partners has an analysts' consensus of $0.63 which suggests that it could grow by 262.32%. Given that P3 Health Partners has higher upside potential than Teladoc Health, analysts believe P3 Health Partners is more attractive than Teladoc Health.

Teladoc Health has a beta of 1.267, which suggesting that the stock is 26.711% more volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Teladoc Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teladoc Health pays -- of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend.

Teladoc Health quarterly revenues are $640.5M, which are larger than P3 Health Partners quarterly revenues of $362.1M. Teladoc Health's net income of -$48.4M is lower than P3 Health Partners's net income of -$46.5M. Notably, Teladoc Health's price-to-earnings ratio is -- while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teladoc Health is 0.54x versus 0.02x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.